A Phase I, Single-blinded, Randomized, Multiple Dose, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Different Dose Escalation Schemes of BI 456906 in Healthy Japanese Male Subject With BMI 23-40 kg/m2
Latest Information Update: 01 Feb 2021
At a glance
- Drugs Survodutide (Primary)
- Indications Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 24 Jan 2021 Status changed from active, no longer recruiting to completed.
- 14 Jan 2021 Planned End Date changed from 31 Dec 2020 to 20 Jan 2021.
- 22 Oct 2020 Status changed from recruiting to active, no longer recruiting.